Information
Regulated Information No.
20226-16-2026Dissemination Date/Time
July 10, 2026 16:52:30Euronext Growth Milan
Company: HELYX INDUSTRIES
User - contact person: ULISSEBIOMEDN02 - SALARIS GABRIELE
Type: REGEM
Reception Date/Time: July 10, 2026 16:52:30 Dissemination Date/Time: July 10, 2026 16:52:30
Subject: GLOBAL CORPORATE FINANCE LLC
SUBSCRIBES THE SECOND TRANCHE OF CAPITAL INCREASE IN EXECUTION
OF THE INVESTMENT AGREEMENT SIGNED ON JULY 31, 2025
Press release text Trieste, July 10, 2026 – Helyx Industries S.p.A. (“Helyx” or the “Company”) (EGM Ticker: HLX), an Italian industrial group active in diagnostics and molecular biology, announces that the subscription and payment by Global Corporate Finance LLC (“GCF”) of a further tranche, the second, of the paid-up and divisible capital increase, with exclusion of pre-emption rights pursuant to articles 2441, paragraphs 5 and 6, of the Italian Civil Code, for a maximum of Euro 2,000,000, including premium, through the issuance of a maximum of 3,000,000 ordinary shares of the Company, resolved by the Company's board of directors (the “Capital Increase”), in execution of the investment agreement signed on July 31, 2025, between the Company and, inter alia, GCF itself (the “Agreement”), have been finalized. Terms indicated below with a capital letter have the meaning attributed to them in the press release of July 31, 2025.
HELYX INDUSTRIES S.P.A.
GLOBAL CORPORATE FINANCE LLC SUBSCRIBES THE SECOND TRANCHE OF CAPITAL INCREASE IN EXECUTION OF THE INVESTMENT AGREEMENT SIGNED ON JULY 31, 2025
CERTIFICATION OF AMENDMENT TO SHARE CAPITAL AND BYLAWS
Trieste, July 10, 2026 – Helyx Industries S.p.A. (“Helyx” or the “Company”) (EGM Ticker: HLX), an Italian industrial group active in diagnostics and molecular biology, announces that the subscription and payment by Global Corporate Finance LLC (“GCF”) of a further tranche, the second, of the paid-up and divisible capital increase, with exclusion of pre-emption rights pursuant to articles 2441, paragraphs 5 and 6, of the Italian Civil Code, for a maximum of Euro 2,000,000, including premium, through the issuance of a maximum of 3,000,000 ordinary shares of the Company, resolved by the Company's board of directors (the “Capital Increase”), in execution of the investment agreement signed on July 31, 2025, between the Company and, inter alia, GCF itself (the “Agreement”), have been finalized. Terms indicated below with a capital letter have the meaning attributed to them in the press release of July 31, 2025.
Specifically, on today's date, GCF, following the Calculation Period initiated by the Company's Subscription Request, and in accordance with the provisions of the Agreement regarding the determination of the number of newly issued shares and their subscription price, has subscribed 394,000 newly issued ordinary shares, without nominal value, admitted for trading on Euronext Growth Milan organized and managed by Borsa Italiana S.p.A., at a unit subscription price of Euro 0.681 (of which Euro 0.01 as capital and Euro 0.671 as premium), for a total consideration of Euro 268,314.00. As a result of this subscription, the total shares issued under the Capital Increase amount to 670,000, out of a maximum of 3,000,000 shares planned.
The proceeds from the Capital Increase are intended, in line with the purposes communicated by the Issuer at the time of signing the Agreement, to support and implement the Company's industrial plan and, in particular, to strengthen the Group's production infrastructure. As part of this investment program, the Company plans interventions on its production site to enhance production and operational capacity in support of the development of next-generation sequencing (NGS) activities within the Mytho division. These interventions are part of the Group's organic growth path along the PCR, deep multiplexing, and NGS value chain.
The recourse to the Capital Increase to support the aforementioned investments reflects a discretionary choice by management, consistent with the typical flexibility of the instrument, aimed at supporting the industrial development program.
It is understood that the conclusion of the Agreement does not represent the only method for raising the necessary resources to implement the industrial plan.
It is also noted that the number of shares subject to this subscription corresponds to the number of Company shares, subject to a securities lending by the Share Lender (so-called Loan Shares), which remained available to GCF following the subscription of the first tranche, as announced on November 5, 2025.
The summary of subscriptions made under the Capital Increase is reported below:
Tranche | Subscription Date | No. of Shares | Unit Price (Euro) | Countervalue (Euro) ------- | ----------------- | ------------- | ----------------- | -------------------
First | October 30, 2025 | 276,000 | 0.960 | 265,000.00 Second | July 10, 2026 | 394,000 | 0.681 | 268,314.00 Total | 670,000 | | | 533,314.00
The current composition of the Company's share capital is shown below, highlighting the previous share capital, also considering the allocation of n. 1,200 newly issued ordinary shares of Helyx Industries S.p.A. resulting from the exercise of n. 1,200 "Warrant Helyx Industries S.p.A. 2021-2026", for a total countervalue of Euro 3,336.00 (for further details, please refer to the press release of June 30, 2026).
| | Current Share Capital | Previous Share Capital | Variation |
|---|---|---|---|
| | Euro | No. of Shares | Euro | No. of Shares | Euro | No. of Shares | | Total | € 264,447.87 | 26,444,787 | € 260,495.87 | 26,049,587 | € 3,952.00 | 395,200 | | of which Ordinary Shares(*) | € 264,447.87 | 26,444,787 | € 260,495.87 | 26,049,587 | € 3,952.00 | 395,200 |
(*) Shares without nominal value
The updated shareholdings based on the information available to the Company are reported below.
Shareholder | No. of Ordinary Shares | %
------------|------------------------|----
Stefano Lo Priore (*) (**) | 3,671,968 | 13.89% Alberto Amati | 2,672,537 | 10.11% Algebris PMI innovative Eltif | 1,700,000 | 6.43% Lorenzo Colombo (**) (***) | 878,703 | 3.32% Copernico Innovazione S.r.l. (**) | 823,597 | 3.11% Nicola Basile (****) | 357,451 | 1.35% Bruna Marini (**) | 224,438 | 0.85% Matteo Petti (**) | 140,900 | 0.53% Market | 15,975,193 | 60.41% Total | 26,444,787 | 100.00%
(*) of which 1,573,249 shares held directly and 2,098,719 shares held through Maximilian Holding LTD.
(**) shareholder party to the Shareholders' Agreement signed on December 21, 2023.
(***) of which 49,000 shares held directly and 829,703 held through Locorian s.s.
(****) of which 77,000 shares held directly and 280,451 held through Bantess s.s.
The certification of the execution of the Capital Increase pursuant to article 2444 of the Italian Civil Code has been filed with the Companies' Register of Udine today, along with the new text of the company's bylaws updated with the new share capital amount.
The new text of the Company's bylaws is also available to the public on the Company's website, www.helyx.bio, section "Investors", subsection "Corporate Governance", as well as on the website of Borsa Italiana S.p.A. in the "Shares/Documents" section. The documentation relating to the Agreement and the Capital Increase is published on the specific page of the Company's website dedicated to the transaction, www.helyx.bio, section "Investors", subsection "Investment Agreement with GCF".
This press release can be consulted online at www.emarketstorage.com and on the Company's website, www.helyx.bio, section "Investors" subsection "Press Releases".
* * *
End of Press Release No. 20226-16-2026 Number of Pages: 5